Login
Navigate Fool.com
Will EPZM beat
the market?

Epizyme

NASDAQ: EPZM

Community Rating: 3 Stars: Appealing

23.35 1.69 (7.80%)

Quote as of

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $21.66
Previous Close $21.66
Daily Range $21.19 - $23.48
52-Week Range $18.10 - $45.72
Market Cap $764.7M
P/E Ratio -98.45
Dividend (Yield) $0.00 (0.0%)
Volume 355,665
Average Daily Volume 330,790
Current FY EPS -$1.96

How do you think EPZM
will perform against the market?

Top EPZM Bull/Bear Pitches

 

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches here!

 

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches here!

News & Commentary

Why Epizyme Inc. Shares Rocketed Higher

Epizyme shares soar after the company reaches another creative milestone with partner GlaxoSmithKline.

What You Ought To Know About Celgene's Deal-Making Magic

Celgene's investment team has made a string of savvy investments in early stage biotech companies.

Stocks: Insiders Buy at Epizyme and Intergrated Device Technology

Plus, purchases at Genocea Biosciences and Gladstone Investment and a sale at Epizyme.

Biotech Boom Set to Smash IPO Record for Two-Week Period

Epizyme Heads Back to Wall Street, Plans $140M Raise

Was Celgene Corporation's Preview Really $2 Billion Worth of Disappointment?

Celgene disappointed investors with a Q4 earnings miss and lower-than-expected 2014 earnings projections. But was the news really that bad?

Celgene's Bet on Epizyme Pays Off

Celgene and Epizyme got a big boost this week when Epizyme's EPZ-5676 met an important milestone.

This Week in Biotech: Putting On a Clinic

In part one of This Week in Biotech we're looking at four encouraging clinical trials, including a company that gained 545%, as well as an announced collaboration and a buyout.

3 Humongous Health-Care Stocks This Week

Intercept Pharmaceuticals, Neurocrine Biosciences, and Epizyme achieve stunning gains in a great week for health-care investors.

Why Neurocrine Biosciences, Epizyme, and Plug Power Are Today's 3 Best Stocks

The S&P 500 delivers its first gain of the year while Neurocrine Biosciences, Epizyme, and Plug Power all rocket higher by at least 39%!

See More EPZM News...

Sector

Industry

Epizyme (EPZM) Description

Website: http://www.epizyme.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks